

UCLA

UCLA Department of Medicine Clinical Insights

Title

When the Immune System Turns on the Joints: Reflections on Checkpoint Inhibitor—Associated Arthritis

Permalink

<https://escholarship.org/uc/item/9bx3f7pb>

Journal

UCLA Department of Medicine Clinical Insights, 1(2)

Author

Aung, Thanda

Publication Date

2026-07-10

DOI

10.5070/V6.63935

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Narrative Medicine Essay

When the Immune System Turns on the Joints: Reflections on Checkpoint Inhibitor–Associated Arthritis

Thanda Aung¹¹ Medicine, University of California, Los Angeles<https://doi.org/10.5070/V6.63935>

UCLA Department of Medicine Clinical Insights

Vol. 1, Issue 2, 2026

She was in her early seventies when I first met her in clinic. Months earlier, she had been diagnosed with metastatic melanoma involving the lungs—a diagnosis that had reshaped her sense of the future. She had started immune checkpoint inhibitor therapy, and her oncologist was cautiously optimistic: recent imaging suggested the treatment was working. She had allowed herself, carefully, to hope.

But something else had begun to happen.

When she sat down across from me, she flexed her fingers slowly, almost experimentally. “My hands don’t work the way they used to,” she said. Morning stiffness now lasted for hours. Her wrists were swollen. Simple tasks—opening jars, fastening buttons, reaching into cabinets—had become unexpectedly difficult. She had assumed the hardest part of her illness was behind her. She had not planned for this.

“I thought the cancer was the hard part,” she said quietly.

On examination, the findings were familiar: swollen, tender knuckles; elevated inflammatory markers; a pattern I had come to recognize in patients receiving immunotherapy. Her blood tests for rheumatoid factor and anti-CCP were negative—not unusual in this setting—but the clinical picture was clear. She had developed inflammatory arthritis as a consequence of the very treatment fighting her cancer.

Immune checkpoint inhibitors work by releasing the brakes the immune system normally keeps on itself. In doing so, they allow T cells to recognize and attack tumor cells with a force they could not summon before. For patients with cancers once considered uniformly fatal, the results have been remarkable. But the immune system, newly unleashed, does not confine its attention to tumors. It can turn against the body’s own tissues—the skin, the gut, the thyroid, the joints. Inflammatory arthritis is among the most recognized of these adverse effects, appearing in a meaningful fraction of patients months into treatment and sometimes persisting long after therapy ends.

“How can the medicine that’s helping me cause this?” she asked.

It was the right question, and there was no easy answer. What I could tell her was that the arthritis was, in a way, a sign that the treatment was active. The same immune activation attacking her tumor was also inflaming her joints. The two were inseparable—which meant that simply stopping immunotherapy was not a straightforward decision. Her oncologist and I remained in close communication, and together we agreed: we would try to control the arthritis without compromising what appeared to be an effective cancer therapy.

We started a low-dose prednisone taper and, once she tolerated it, added methotrexate. She continued her checkpoint inhibitor throughout. The weeks that followed were not easy. She came to appointments with her hands wrapped, moving carefully. She asked practical questions—could she still drive, manage her medications, would this improve? She did not complain. What she seemed to want most was honest information and the reassurance that someone understood what she was experiencing.

Gradually, the swelling in her hands began to improve. Some stiffness persisted, and I did not promise complete resolution. But over several months, she regained enough function to return to the activities that mattered to her. At one visit, almost in passing, she mentioned that she had gone back to her garden. Slowly, she said—but she was out there.

I think about her often when I consider what it means to practice medicine in this era. Checkpoint inhibitors have extended survival for patients whose cancers were, not long ago, considered unsurvivable. They have also introduced a new kind of patient into rheumatology clinics—individuals managing autoimmune disease not despite their cancer treatment, but because of it. The condition and the therapy are intertwined. It is not always possible to separate what heals from what harms.

As she was leaving one visit, she paused at the door. “If this medicine keeps the cancer away,” she said, “I can live with some arthritis.”

Her equanimity felt both hard-won and genuine. What she had arrived at—a willingness to hold two difficult realities at once—is not something medicine trains us for. We are taught to solve problems, to fix what is broken, to move toward resolution. But some patients must live within an enduring tension. In those moments, our role is not only to manage inflammation or adjust medications, but to help

patients name what they are living with—and to remain present with them in that uncertainty.

The immune system she now carries is newly unleashed. It has turned, in part, against her. And it may also be what keeps her alive.



This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CCBY-4.0). View this license's legal deed at <http://creativecommons.org/licenses/by/4.0> and legal code at <http://creativecommons.org/licenses/by/4.0/legalcode> for more information.

REFERENCES

1. Defoe M, Bermas BL. Rheumatologic immune checkpoint inhibitor-related adverse events. *Curr Opin Rheumatol*. 2023;35(3):141-148. doi:[10.1097/BOR.0000000000000935](https://doi.org/10.1097/BOR.0000000000000935)
2. Cappelli LC, Gutierrez AK, Bingham CO 3rd, Shah AA. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. *Arthritis Care Res (Hoboken)*. 2017;69(11):1751-1763. doi:[10.1002/acr.23177](https://doi.org/10.1002/acr.23177)
3. Bass AR, Xie F, Jannat-Khah D, et al. Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study. *Rheumatology (Oxford)*. 2025;64(4):1637-1642. doi:[10.1093/rheumatology/keae343](https://doi.org/10.1093/rheumatology/keae343)
4. Ghosh N, Tionson MD, Stewart C, et al. Checkpoint inhibitor-associated arthritis: a systematic review of case reports and case series. *J Clin Rheumatol*. 2021;27(8):e317-e322. doi:[10.1097/RHU.0000000000001370](https://doi.org/10.1097/RHU.0000000000001370)
5. Ghosh N, Jivanelli B, Couette N, et al. The need for classification criteria of immune checkpoint inhibitor-induced inflammatory arthritis: a scoping review. *Rheum Dis Clin North Am*. 2024;50(2):325-335. doi:[10.1016/j.rdc.2024.02.006](https://doi.org/10.1016/j.rdc.2024.02.006)